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ABSTRACT 
Chlamydia trachomatis is a major cause of sexually transmitted diseases worldwide.  There 
currently is no vaccine to protect against chlamydial infection of the female reproductive 
tract.  Vaccine development has predominantly involved using the murine model, however 
infection of female guinea pigs with Chlamydia caviae more closely resembles chlamydial 
infection of the female reproductive tract, and presents a better model to assess potential 
human chlamydial vaccines.  We immunised female guinea pigs intranasally with 
recombinant major outer membrane protein (r-MOMP) combined with CpG-10109 and 
cholera toxin adjuvants.  Both systemic and mucosal immune responses were elicited in 
immunised animals, with MOMP-specific IgG and IgA present in the vaginal mucosae, and 
high levels of MOMP-specific IgG detected in the serum.  Antibodies from the vaginal 
mucosae were also capable of neutralising C. caviae in vitro.  Following immunisation, 
animals were challenged intravaginally with 102 inclusion forming units of live C. caviae.  We 
observed a decrease in duration of infection and a significant (p<0.025) reduction in infection 
load in r-MOMP immunised animals, compared to animals immunised with adjuvant only.  
Importantly, we also observed a marked reduction in upper reproductive tract (URT) 
pathology in r-MOMP immunised animals.  Intranasal immunisation of female guinea pigs 
with r-MOMP was able to provide partial protection against C. caviae infection, not only by 
reducing chlamydial burden but also URT pathology.  This data demonstrates the value of 
using the guinea pig model to evaluate potential chlamydial vaccines for protection against 
infection and disease pathology caused by C. trachomatis in the female reproductive tract. 
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1. INTRODUCTION 
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen 
worldwide and presents a serious health threat due to the high burden of disease that can 
result from infection of the female reproductive tract (WHO, 2001).  In women, C. 
trachomatis normally infects the columnar epithelium of the endocervix (Soong et al., 1990).  
Following replication, the bacteria can ascend to the upper reproductive tract (URT)1, with a 
recent mathematical model suggesting that the degree of ascension is dependent on the 
interaction between the innate immune response and the passive movement of Chlamydia 
(Mallet et al., 2009).  Once in the URT, the organism can establish a persistent infection that 
may lead to pelvic inflammatory disease, ectopic pregnancy or infertility (Weström et al., 
1992).  Infection can be resolved with antimicrobial treatment, however 70-90% of infected 
women are asymptomatic, resulting in a large number of cases going undiagnosed and 
untreated (Stamm and Holmes, 1990).  It has been proposed that the development of a 
prophylactic chlamydial vaccine, that protects against URT pathology, would significantly 
reduce the disease impact and associated economic cost of C. trachomatis infections (de la 
Maza and de la Maza, 1995; Gray et al., 2009). 
Early studies of chlamydial vaccines utilised whole inactivated elementary bodies to induce 
protection against ocular C. trachomatis infection.  However in these trials, a stronger 
immune response actually correlated with a more pronounced disease state (Grayston et al., 
1961).  Subsequent vaccine research has focused on selecting specific proteins of the 
pathogen that are immunogenic and avoid the immune related pathology associated with 
use of the whole chlamydial organism.  The major outer membrane protein (MOMP) has 
frequently been identified as a promising vaccine candidate (Baehr et al., 1998; de la Maza 
and Peterson, 2002).  It is present throughout all stages of the C. trachomatis developmental 
cycle and is recognised in most species as an immunodominant antigen (Zhang et al., 
1993).  Our group has previously demonstrated that combining MOMP with CpG and cholera 
toxin adjuvants, and delivering via either the intranasal (Cunningham et al., 2009) or 
transcutaneous route (Berry et al., 2004), stimulates a strong immune response and 
provides partial protection against Chlamydia muridarum reproductive tract infection in mice. 
To date, the majority of chlamydial vaccine studies have been performed in mice (Cochrane 
et al., 2010), however reproductive tract infection of this species does not accurately reflect 
sexually transmitted chlamydial infection in humans.  Potential vaccines need to be 
evaluated in a model that more closely parallels humans in terms of infection course and 
pathological response.  Very few vaccine candidates have been explored in the guinea pig 
model of C. caviae reproductive tract infection (Batteiger et al., 1993; Rank et al., 1990), 
despite the model being used strategically to investigate immune responses and infection 
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kinetics (Rank et al., 1979, 1982, 1988, 1989, 2000; Wang et al., 2010).  Female guinea pigs 
have a 15-17 day oestrous cycle (Stockard and Papanicolaou, 1919), comparable to the 28 
day menstrual cycle in humans.  This is important as the vaginal mucosae is affected by the 
release of sex hormones, which can influence immune response to infection (Rank et al., 
1982).  Chlamydial infection of the reproductive tract in guinea pigs can also progress to a 
disease state that closely resembles clinical disease seen at this site in humans (Rank and 
Sanders, 1992).  In addition, guinea pigs are the only known species to have had the 
sexually transmitted infective dose of Chlamydia characterised (Rank et al., 2003).  Animals 
are typically given a high infective dose of Chlamydia, as well as progesterone pre-treatment 
in the murine model, to guarantee infection (Rank et al., 2003; Vanrompay et al., 2006).  
However, this approach does not accurately assess the protective function of a vaccine 
(Rank et al., 2003) and can lead to inconsistent findings across a particular model (Ahmad et 
al., 1977).  By challenging guinea pigs intravaginally with a natural infective dose of C. 
caviae post immunisation, it is possible to correlate the infection course and pathological 
response to that observed in humans, presenting a better model with which to evaluate 
chlamydial vaccines.   
Results of a previous study (Batteiger et al., 1993) showed that female guinea pigs produced 
an immune response and a reduced infection course following subcutaneous immunisation 
with native MOMP, however protection against URT pathology was not investigated.  We 
report here the first intranasal immunisation of guinea pigs with recombinant C. caviae 
MOMP (r-MOMP) combined with CpG and CT, which stimulated both systemic and mucosal 
immune responses and provided partial protection against C. caviae intravaginal infection, 
measured as a decrease in duration and intensity of infection, as well as reduced pathology 
in the URT of these animals. 
  
2. MATERIALS AND METHODS 
2.1. Guinea Pigs 
Sexually mature (600-800 g), female, random outbred English short haired (ROES) guinea 
pigs were obtained from the Institute of Medical and Veterinary Science (IMVS; Gilles Plain, 
SA, AU) and housed at the Herston Medical Research Centre (HMRC; Brisbane, QLD, AU).  
Animals were placed in individual mini isolators (Able Scientific, Canning Vale, WA, AU) and 
kept in an environmentally controlled room at 21°C on a 12 h light/12 h dark cycle.  They 
were fed standard guinea pig pellets and tap water supplemented with 4 mg/20 L ascorbic 
acid ad libitum.  All procedures involving animals were approved by the Queensland 
University of Technology University Animal Ethics Research Committee (QUT UAEC No. 
0700000346).   
 
2.2. Recombinant MOMP Expression and Purification 
The CCA-00047 gene (C. caviae MOMP; GenBank ID: AAP04799.1) was synthesised and 
cloned into a pCold TF expression vector (performed by GenScript Corporation, Piscataway, 
NJ, US).  pCold TF-CCA-00047 was transformed into Escherichia coli Origami B (DE3) cells 
(Novagen, Darmstadt, DE) for expression of recombinant C. caviae MOMP.  Transformed E. 
coli were incubated in Lysogeny broth (LB) at 37°C to reach mid-log phase, then induced 
with 5 mM IPTG (Quantum Scientific, Murarrie, QLD, AU) for 4 h at 15°C.  Bacterial cultures 
were harvested by centrifugation at 4,650 g for 10 mins at 4°C.  E. coli were lysed by 
incubation with lysozyme (Sigma-Aldrich), then sonicated following addition of Protease 
Inhibitor Cocktail (Sigma-Aldrich) and PMSF (Sigma-Aldrich).  Inclusion bodies were 
solubilised with 4 M urea for 4 h at 4°C, then centrifuged at 4,650 g for 10 mins at 4°C.  
Supernatant was purified and concentrated as previously described (Barker et al., 2008).  r-
MOMP was quantified via BCA protein assay (Thermo Scientific, Scoresby, VIC, AU). 
 
2.3. Immunisation Protocol 
Guinea pigs were lightly sedated with 2-4% Isoflurane inhalation anaesthesia (Abbott 
Australasia, Botany, NSW, AU) in 4 L/min oxygen.  Synthetic CpG-10109 (Gu et al., 2007) 
oligonucelotides (Sigma-Aldrich) and cholera toxin (CT; Sapphire Bioscience, Waterloo, 
NSW, AU) were used as adjuvants in each immunisation.  r-MOMP/CpG/CT guinea pigs 
(n=5) were administered 100 µg r-MOMP, 25 µg CpG, 10 µg CT.  CpG/CT guinea pigs (n=5) 
were given 25 µg CpG, 10 µg CT only.  Each group was successfully immunised intranasally 
with 150-200uL three times at weekly intervals, and given a final immunisation booster two 
weeks following third immunisation.  Immunisations were equally distributed to nares of each 
animal using a micropipette. 
 
2.4. Live C. caviae Infection Challenge and Vaginal Swab Collection 
C. caviae (ATCC VR-813; Manassas, VA, US) was grown on McCoy cells, then semi-
purified (Rank et al., 1988).  Animals were lightly sedated as described in section 2.3.  Each 
guinea pig then was given 25 µL sterile PBS containing 102 inclusion forming units (IFUs) of 
live C. caviae, via micropipette into the vagina.  Infection was monitored by collecting 
cervico-vaginal swabs every three days until day 27.  Swabs were placed in 500 µL sucrose-
phosphate-glutamate (SPG) with 3x sterile glass beads, and vortexed before storage at -
80°C.  The C. caviae infection course was determined by infecting McCoy cells with swab 
eluate, then stopping with 100% methanol fixation 30 h post infection and staining with a 
FITC-conjugated monoclonal antibody (Chlamydia Cel LPS Reagent; Cellabs Pty Ltd, 
Brookvale, NSW, AU).  IFUs were counted using a fluorescence microscope. 
 
2.5. Collection of Serum and Vaginal Washes 
Blood and vaginal washes were obtained from anaesthetised guinea pigs prior to 
immunisation and one week following the final immunisation booster.  Blood was collected 
from the saphenous leg vein (Lopez and Navia, 1997) and allowed to clot at room 
temperature for 1 h.  Serum was acquired by centrifuging clotted blood at 12,000 g for 30 
mins.  Vaginal washes were collected by flushing  the vagina 3x with 200 µL sterile PBS.  
Serum and vaginal washes were stored at -20°C until required. 
 
2.6. ELISA Analysis 
MOMP-specific IgG and IgA titres were determined for serum and vaginal washes using 
previously described methods (Carey et al., 2009).  ELISA 96 well plates (Grenier Bio-One 
med. binding; Interpath Services, Heidelberg West, VIC, AU) were coated with 0.5 µg r-
MOMP protein/well.  Serum and vaginal washes initially were diluted 1:2000 and 1:25 
respectively.  Samples then were serially diluted twofold in PBS-Tween (PBS-T) and added 
to wells in duplicate.  For IgG detection, 1:1000 rabbit anti-guinea pig IgG (H+L) HRP (MP 
Biomedicals, Solon, OH, US) in PBS-T was added to each well.  This was repeated for 
detection of IgA, but with rabbit anti-guinea pig IgA (α-chain) (MP Biomedicals) in PBS-T 
instead.  Following incubation, 1:1000 goat anti-rabbit IgG (H+L) HRP (MP Biomedicals) in 
PBS-T was added to IgA wells.  TMB substrate (Sigma-Aldrich), diluted 1:100 with 
Phosphate Citrate Buffer (PCB; Sigma-Aldrich), was added to all wells.  Colour development 
was stopped by adding 1 M sulphuric acid.  Absorbance values were measured at 450 nm 
with a Bio-Rad xMarkTM Microplate Spectrophotometer.  Samples collected from animals 
prior to immunisation were used as negative controls to determine end point titre (EPT) 
values.  EPT was calculated as the inverse of the dilution, where absorbance values were 
equivalent to the mean of the negative control + two standard deviations. 
 
2.7. in vitro Neutralisation Assay 
Serum and vaginal washes collected from each animal prior to immunisation (pre), and one 
week following the final immunisation booster (post), were diluted 1/5 and 1/25 respectively 
in media in 96 well microplates.  Each well was incubated with 7.5x103 IFUs of C. caviae for 
1 h at 37°C.  Following incubation, the contents of each well were transferred to 
corresponding wells of 96 well microplates containing 80% confluent McCoy cell 
monolayers.  Infection proceeded to 30 h as described in section 2.4.  Following staining, 
infectivity (the number of C. caviae IFUs per the number of McCoy cells) was determined 
using a fluorescence microscope.  Neutralisation was calculated by comparing the change in 
infectivity between pre and post samples for each animal. 
 
2.8. Histopathology Assessment of Reproductive Tract 
Guinea pigs were euthanised by intracardiac injection of 1 mL/2 kg sodium pentobarbitone 
(Lethabarb; Abbott Australasia) four weeks following C. caviae infection.  Reproductive tracts 
were surgically removed and fixed in 10% Neutral Buffered Formalin for one week.  For each 
animal; cervix, uterus (uterine corpus, 2x uterine horns), 2x oviducts and 2x ovaries, were 
embedded in paraffin wax, sectioned at 5 µm and haematoxylin and eosin (H+E) stained 
(performed by Dr. John Mackie).  Each anatomic site was scored for acute inflammation, 
chronic inflammation and plasma cell infiltration using a histopathological assessment 
method adapted from a previously published system (Rank et al., 1992): trace of parameter, 
+0.5 (low); presence of parameter, +1 (mild); presence of parameter at 1 to 4 foci 
(moderate), +2; presence of parameter at >4 foci, +3 (marked); confluent presence of 
parameter, +4 (severe). 
 
2.9. Statistics 
All statistical analyses were performed using GraphPad Prism v.5.  Statistical significance 
was determined using unpaired, two-tailed Student’s t-test with 95% confidence interval 
(C.I.). 
  
3. RESULTS 
3.1. r-MOMP immunisation stimulates MOMP-specific antibody response 
Serum collected from r-MOMP immunised animals one week following immunisation booster 
had significantly higher (p<0.001) levels of MOMP-specific IgG (>100 000 EPT) when 
compared to serum from animals immunised with CpG/CT only (Fig. 1A).  In vaginal washes, 
MOMP-specific IgG and IgA antibodies were present at significantly higher (p<0.001) levels 
in animals that received r-MOMP immunisation, compared to those immunised with CpG/CT 
(Fig. 1B,1C).  No MOMP-specific IgA was recorded in the serum of r-MOMP or CpG/CT 
immunised animals.  All animals were negative for MOMP-specific IgG and IgA antibodies in 
the serum and vaginal washes prior to immunisation. 
 
3.2. r-MOMP induced vaginal antibodies partially neutralise C. caviae infection in vitro 
The infectivity was determined in both pre- and post- immunisation samples of individual 
animals at 1/25 dilution, and neutralisation was calculated by comparing the change in 
infectivity between these two samples.   r-MOMP immunised animals showed a 22.5% 
increase in in vitro neutralisation of C. caviae compared to CpG/CT immunised animals (Fig. 
2).  All immunisation parameters and components for guinea pigs receiving CpG/CT 
immunisation were kept consistent with r-MOMP immunised animals; therefore any 
difference in neutralisation between these groups is attributed to immunisation with r-MOMP 
protein.  Whilst a difference in in vitro neutralisation in vaginal washes was observed 
between r-MOMP and CpG/CT immunised animals, no difference in neutralisation occurred 
when testing the serum collected from these animals (data not shown). 
 
3.3. r-MOMP immunisation reduces the intensity and duration of live C. caviae 
infection 
Following intranasal immunisation with r-MOMP, animals were challenged intravaginally with 
a low dose (102 IFU) of live C. caviae.  Some animals did not become infected, determined 
by the absence of C. caviae IFUs from the vaginal swab samples collected.  Only 2/5 (40%) 
of r-MOMP immunised animals, and 3/5 (60%) of CpG/CT immunised animals demonstrated 
an active infection.  CpG/CT immunised animals had a peak of infection at day 18 (Fig. 3A), 
with shedding levels >4.0x105 IFU.  r-MOMP/CpG/CT immunised animals showed signs of 
reduced infection intensity, with shedding levels peaking significantly lower (p<0.025)  at 
<1.5x105 IFU,  6 days earlier.  This group was able to clear infection by day 21, whereas 
CpG/CT immunised animals did not clear the infection until day 27.  Area under the curve 
analysis of C. caviae infected animals (Fig. 3B) demonstrates that the r-MOMP/CpG/CT 
immunised group had a reduced course of infection compared to the CpG/CT immunised 
group. 
  
 3.4. r-MOMP immunisation reduces URT pathology 
In the lower reproductive tract (LRT) of both r-MOMP and CpG/CT immunised animals, 
moderate acute inflammation was seen in the cervix four weeks follow infection (Fig. 4A).  
However, only low chronic inflammation was observed in r-MOMP immunised animals, whilst 
moderate chronic inflammation was seen in CpG/CT immunised animals. 
In the URT of animals that received r-MOMP immunisation, mild acute inflammation was 
observed in the uterus (Fig. 4B), and mild acute and chronic inflammation in the ovaries (Fig. 
4C + 4D).  Conversely, in those animals that received CpG/CT immunisation only, moderate 
acute inflammation was observed in the uterus, with marked acute and chronic inflammation 
in the ovaries. 
Whilst tissues were collected, processed and analysed from all animals, only those that 
demonstrated an active infection following C. caviae challenge were included in the results 
of this study.  Hydrosalpinx development was not seen in the fallopian tubes and no signs of 
pathology were observed in the fallopian tubes microscopically.  No fibrosis or mucosal 
erosion was present in any samples. 
  
4. DISCUSSION 
This is the first report of partial protection against live intravaginal C. caviae challenge by 
intranasal r-MOMP immunisation in the female guinea pig model of reproductive tract 
infection.  Intranasal immunisation of female guinea pigs with r-MOMP/CpG/CT induced 
MOMP-specific IgG and IgA responses in the vaginal mucosae, and a strong MOMP-specific 
IgG response in the serum.  This indicates that the subunit vaccine stimulated both the 
systemic and mucosal immune systems when delivered intranasally.  Antibodies generated 
in the vaginal mucosae were also able to partially neutralise C. caviae infection in vitro, 
suggesting that these antibodies could recognise live C. caviae locally and prevent an active 
infection.  Although in vitro neutralisation of C. caviae was observed in vaginal washes, no 
neutralisation occurred when immune serum was assayed, which may be due to the 
absence of MOMP-specific IgA in serum. 
Whilst it is known that CT and CpG adjuvants induce innate immunity (Klinman et al., 2000; 
Matsuo et al., 2000), we specifically wanted to measure the effect of the chlamydial antigen 
above the adjuvant only effect in providing protection in guinea pigs against chlamydial 
reproductive tract infection.  As such, we chose to compare r-MOMP/CpG/CT immunised 
animals with an adjuvant only (CpG/CT) control group.  All animals were challenged 
intravaginally with 102 IFU of live C. caviae.  Of the r-MOMP immunised animals, 40% 
became infected, compared to 60% in the adjuvant only (CpG/CT) group.  The peak of 
infection in the r-MOMP group was significantly lower (p<0.025) than the adjuvant only 
group.  This may have led to enhanced development of URT pathology in CpG/CT 
immunised animals, as a higher infectious load could ascend from the LRT (Mallet et al., 
2009).  Increased acute and chronic inflammation was seen in the ovaries and uterus of the 
adjuvant only group, although the fallopian tubes showed no signs of inflammation, and no 
gross abnormalities were observed.  The majority of chlamydial studies investigating female 
URT pathology have frequently identified the fallopian tubes as being one of the most 
affected areas, in guinea pigs (Rank et al., 1993) as well as other species (Cunningham et 
al., 2010; Schautteet et al., 2010).  The lack of fallopian tube pathology may have been due 
to the low chlamydial infective dose administered.  This is the first study to investigate URT 
pathology following challenge with a realistic chlamydial dose that approximates the natural 
infective dose from sexual transmission (Rank et al., 2003), and was not expected to cause 
the same pathology seen in animals that are given a high infective dose of live Chlamydia.  
This characterises what may be seen in human females, as not all C. trachomatis infections 
may ascend to the URT (Brunham and Rey-Ladino, 2005).  Recent reports also highlight the 
need for additional modifications to our current guinea pig model of chlamydial reproductive 
tract infection, to further reflect important biological processes in women that impact 
chlamydial pathogenesis.  This includes defining the stage of the menstrual cycle at the time 
of infection and the potential effect of innate immune mediators present in the male seminal 
fluid that would be transferred at coitus (Lyons et al., 2009), as well as establishing 
prolonged infections following immunisation (Miyairi et al., 2010), which would likely improve 
the efficacy of the guinea pig model in testing vaccine efficiencies 
MOMP has been established in most species as a  dominant antigen recognised by the 
humoral immune system during chlamydial reproductive tract infection (Caldwell and 
Schachter, 1982).  Previous work by our group has shown that combining MOMP with the 
potent CpG and cholera toxin adjuvants that induce TH1 and TH2 responses respectively, 
and delivering via intranasal immunisation, is able to generate a MOMP-specific immune 
response in mice systemically and in the vaginal mucosae (Barker et al., 2008; Cunningham 
et al., 2009).  We have confirmed those findings in this study, showing that intranasal 
immunisation of guinea pigs with a subunit vaccine  elicits both systemic and mucosal 
antibody responses that provide partial protection.  We are currently developing methods to 
analyse vaccine-induced mucosal cell-mediated immunity in outbred guinea pigs, to evaluate 
the role of T cell responses in protection. 
A vaccine that provides protection against upper reproductive tract pathology caused by C. 
trachomatis, would considerably reduce the global disease burden and associated impact of 
this sexually transmitted infection (de la Maza and de la Maza, 1995; Gray et al., 2009).  The 
guinea pig model of chlamydial reproductive tract infection closely parallels humans in terms 
of infection course and pathological response (Rank and Sanders, 1992) and should 
continue to be used to explore the efficacy of potential vaccine candidates against C. 
trachomatis infection of the human female reproductive tract. 
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FIGURE LEGENDS 
Fig. 1 -  MOMP-specific antibody levels in serum and vaginal washes collected one week 
following immunisation booster: (A) MOMP-specific IgG EPT in serum, (B) MOMP-specific 
IgG EPT in vaginal washes, (C) MOMP-specific IgA EPT in vaginal washes.  Serum and 
vaginal washes collected from animals prior to immunisation were used as controls.  n = 5 
animals per group.  Bars represent SEM.  Statistical significance was obtained using 
unpaired, two-tailed Student’s T-test with 95% C.I. 
Fig. 2 -  in vitro neutralisation of C. caviae by vaginal washes.  Samples diluted 1/25.  
Percentage neutralisation for individual animals determined using equation; (pre immune 
infectivity – post immune infectivity)/pre immune infectivity. n = 5 animals per group.  Bars 
represent SEM. 
Fig. 3 -  (A) Partial protection observed in r-MOMP immunised animals against intravaginal 
C. caviae challenge; reduced duration and intensity of infection compared to CpG/CT 
immunised animals.  Swabs collected every three days following challenge until day 27. (B) 
Area under the curve analysis of course of infection.  n (CpG/CT) = 3 animals, n (r-MOMP) = 
2 animals.  Bars represent SEM.  Statistical significance was obtained using unpaired, two-
tailed Student’s T-test with 95% C.I. 
Fig. 4 -  Histopathology assessment of LRT and URT, scored for acute inflammation 
(neutrophil infiltration), chronic inflammation (lymphocyte infiltration) and plasma cells: (A) 
cervix - LRT, (B) uterus (uterine corpus, 2x uterine horns) - URT, (C) ovaries (left and right) - 
URT.  n (CpG/CT) = 3 animals, n (r-MOMP) = 2 animals.  Bars represent SEM. 
 
